Immune checkpoint inhibitors in melanoma
Immune checkpoint inhibitors target the dysfunctional immune system, to induce cancer-cell
killing by CD8-positive T cells. Immune checkpoint inhibitors, specifically anti-CTLA4 and …
killing by CD8-positive T cells. Immune checkpoint inhibitors, specifically anti-CTLA4 and …
Top 10 challenges in cancer immunotherapy
Cancer immunotherapy is a validated and critically important approach for treating patients
with cancer. Given the vast research and clinical investigation efforts dedicated to advancing …
with cancer. Given the vast research and clinical investigation efforts dedicated to advancing …
Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase …
RK Kelley, B Sangro, W Harris, M Ikeda… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte–
associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand …
associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand …
Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma
JL Vos, JBW Elbers, O Krijgsman, JJH Traets… - Nature …, 2021 - nature.com
Surgery for locoregionally advanced head and neck squamous cell carcinoma (HNSCC)
results in 30‒50% five-year overall survival. In IMCISION (NCT03003637), a non …
results in 30‒50% five-year overall survival. In IMCISION (NCT03003637), a non …
Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial
In patients with previously treated metastatic uveal melanoma, the historical 1 year overall
survival rate is 37% with a median overall survival of 7.8 months. We conducted a …
survival rate is 37% with a median overall survival of 7.8 months. We conducted a …
Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma
PURPOSE The combination of talimogene laherparepvec (T-VEC) and pembrolizumab
previously demonstrated an acceptable safety profile and an encouraging complete …
previously demonstrated an acceptable safety profile and an encouraging complete …
Neoadjuvant PD-1 blockade in resectable lung cancer
Background Antibodies that block programmed death 1 (PD-1) protein improve survival in
patients with advanced non–small-cell lung cancer (NSCLC) but have not been tested in …
patients with advanced non–small-cell lung cancer (NSCLC) but have not been tested in …
Hyperprogressive disease in patients with advanced non–small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy
R Ferrara, L Mezquita, M Texier, J Lahmar… - JAMA …, 2018 - jamanetwork.com
Importance Hyperprogressive disease (HPD) is a new pattern of progression recently
described in patients with cancer treated with programmed cell death 1 (PD-1) and …
described in patients with cancer treated with programmed cell death 1 (PD-1) and …
Current state of immunotherapy for glioblastoma
M Lim, Y Xia, C Bettegowda, M Weller - Nature reviews Clinical …, 2018 - nature.com
Glioma is the most common primary cancer of the central nervous system, and around 50%
of patients present with the most aggressive form of the disease, glioblastoma. Conventional …
of patients present with the most aggressive form of the disease, glioblastoma. Conventional …
[HTML][HTML] Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
S Gao, N Li, S Gao, Q Xue, J Ying, S Wang… - Journal of Thoracic …, 2020 - Elsevier
Introduction Programmed death receptor-1 (PD-1) inhibitors have shown efficacy in first-line
treatment of NSCLC; however, evidence of PD-1 inhibitor as neoadjuvant treatment is …
treatment of NSCLC; however, evidence of PD-1 inhibitor as neoadjuvant treatment is …